UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Neurology, 2020-08, Vol.95 (8), p.e943

2020

Volltextzugriff (PDF)

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Neurology, 2021-08, Vol.97 (8), p.e803

2021

Volltextzugriff (PDF)

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

PloS one, 2022-06, Vol.17 (6), p.e0269154-e0269154

2022

Volltextzugriff (PDF)

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Scientific reports, 2022-09, Vol.12 (1), p.15713-15713, Article 15713

2022

Volltextzugriff (PDF)

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5065

2023

Volltextzugriff (PDF)

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

NeuroImage clinical, 2020-01, Vol.28, p.102385-102385, Article 102385

2020

Volltextzugriff (PDF)

Clinical studies in amyotrophic lateral sclerosis

Current opinion in neurology, 2022-10, Vol.35 (5), p.686-692

2022

Volltextzugriff (PDF)

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

NeuroImage clinical, 2024-01, Vol.43, p.103633, Article 103633

2024

Volltextzugriff (PDF)

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Neurology, 2019-06, Vol.92 (23), p.e2661

2019

Volltextzugriff (PDF)

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

PM & R, 2015-07, Vol.7 (7), p.677-684

2015

Volltextzugriff (PDF)

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Chest, 2011-10, Vol.140 (4), p.687A-687A

2011

Volltextzugriff (PDF)

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

BMC musculoskeletal disorders, 2013-05, Vol.14 (S2), p.P1-P1, Article P1

Genge, Angela

2013

Volltextzugriff (PDF)

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Neurology, 2021-02, Vol.96 (6), p.e853

2021

Volltextzugriff (PDF)

Amyotrophic Lateral Sclerosis (ALS) Genetic Testing: Current Landscape and Potential Needs (2691)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (P1-13.001)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Neurology, 2019-04, Vol.92 (14), p.e1610

2019

Volltextzugriff (PDF)

Spinraza in Adults with Spinal Muscular Atrophy (SAS) – 14 month results (S33.010)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS) (2474)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Structural and Neurometabolic Correlates of Motor Neuron Function in ALS: A Multimodal fMRI-MRS-DTI-Texture Intersection Study (2297)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1 – 25 von 59

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

KollektioneBooks on EBSCOhost

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(59)

Sprache

Englisch
(59)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(17)
Neurosciences & Neurology
(14)
Humans
(13)
Clinical Neurology
(11)
Female
(10)
Male
(10)
Middle Aged
(10)
Adult
(9)
Aged
(8)
Amyotrophic Lateral Sclerosis
(8)
Double-Blind Method
(5)
Magnetic Resonance Imaging
(4)
Aged, 80 And Over
(3)
Amyotrophic Lateral Sclerosis - Drug Therapy
(3)
Amyotrophic Lateral Sclerosis - Pathology
(3)
Diffusion Tensor Imaging
(3)
Myasthenia Gravis - Drug Therapy
(3)
Neuroimaging
(3)
Treatment Outcome
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

Clinical studies in amyotrophic lateral sclerosis

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Amyotrophic Lateral Sclerosis (ALS) Genetic Testing: Current Landscape and Potential Needs (2691)

24-Week Results From Phase 3 Study MT-1186-A01 an Open-Label, Multicenter Safety Study of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (P1-13.001)

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

Spinraza in Adults with Spinal Muscular Atrophy (SAS) – 14 month results (S33.010)

The Comprehensive Analysis Platform To Understand, Remedy, and Eliminate ALS (CAPTURE ALS) (2474)

Structural and Neurometabolic Correlates of Motor Neuron Function in ALS: A Multimodal fMRI-MRS-DTI-Texture Intersection Study (2297)

Aktive Filter

Suchergebnisse filtern